HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the United States that specializes in developing innovative cell and gene immunotherapies for the treatment of cancer and autoimmune diseases. The company focuses on chimeric antigen receptor therapies to address multiple myeloma and other forms of cancer. Cartesian Therapeutics employs its proprietary ImmTOR immune tolerance platform, which aims to foster antigen-specific immunity while reducing unwanted immune responses. This approach utilizes a manufacturing platform to introduce mRNA molecules into cells, enhancing their functionality without the risk of integration into the cell's genetic material, as mRNA naturally degrades over time.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

1000Farmacie is a prominent pharmacy marketplace in Italy that operates an online shopping platform dedicated to providing a diverse selection of pharmaceutical products. By collaborating with a network of independent pharmacies, the company ensures that customers can purchase healthcare items at competitive prices. The platform offers the convenience of same-day delivery to specified locations, enabling users to save both time and money while accessing essential health products.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on the research, discovery, and development of drugs for central nervous system disorders. Founded in 2011 and headquartered in Seongnam, the company is advancing several clinical candidates, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome. Additionally, Relenopride is in Phase 2 trials for a rare neurological disease, while SKL13865, SKL20540, SKL-PSY, and SKL24741 are in various early-phase trials for conditions such as attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to become a leading specialty pharmaceutical company by developing innovative therapies for CNS and metabolic disorders, alongside providing specialized pharmaceutical manufacturing services.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Visen Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for endocrine diseases. The company is dedicated to addressing significant unmet medical needs in this field, particularly within the Chinese market, and aims to provide both first-in-class and best-in-class treatment solutions for patients of all ages, including those with rare endocrine conditions. With a commitment to patient-centric care, Visen strives to improve treatment outcomes and quality of life for individuals affected by these diseases. The company is backed by a team of experienced professionals with extensive backgrounds in the pharmaceutical industry and operates offices in major Chinese cities such as Shanghai, Beijing, Hong Kong, and Taipei. To further enhance its research, development, and manufacturing capabilities, Visen has established a Greater China research and development site in Suzhou, aiming to deliver advanced treatment options to Chinese patients more effectively.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, it operates as a wholly owned subsidiary of Biohaven Pharmaceuticals. The company specializes in late-stage product candidates and utilizes clinical trial platforms to explore treatments such as calcitonin gene-related peptide (CGRP) receptor antagonism for migraine and pain, glutamate modulation for Alzheimer’s disease and anxiety disorder, and myeloperoxidase (MPO) inhibition for inflammation and neurodegeneration. BioShin aims to address unmet medical needs in the neurological field, particularly within the Asia-Pacific market.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Polyneuron Pharmaceuticals AG is a biotechnology company based in Basel, Switzerland, founded in 2014. The company focuses on developing innovative therapeutics for antibody-mediated autoimmune disorders, particularly those affecting the peripheral nervous system. Its lead candidates include PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron employs a unique platform technology called Antibody-Catch, which utilizes biodegradable glycopolymers to selectively target and eliminate pathogenic autoantibodies while preserving the overall integrity of the immune system. This approach aims to provide safe and effective treatment options for patients suffering from these complex immune disorders.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing innovative therapies for gastrointestinal and immunological diseases. Headquartered in Dublin, Ireland, with an additional office in Solana Beach, California, the company aims to address unmet clinical needs through its proprietary oral drug delivery technology. This technology enhances the bioavailability of difficult-to-formulate drugs, allowing for effective systemic or localized delivery within the gastrointestinal tract. Sublimity Therapeutics' product portfolio includes treatments for conditions such as ulcerative colitis, Crohn’s disease, graft versus host disease, and transplant rejection, as well as SmPill formulations for various gastrointestinal disorders. The company's lead product is STI-0529, specifically designed for moderate to severe ulcerative colitis. Founded in 2000 and formerly known as Sigmoid Pharma, Sublimity Therapeutics is committed to advancing oral pharmaceutical formulation technologies to improve patient outcomes in its targeted therapeutic areas.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company focuses on licensing, developing, and commercializing innovative therapies to meet critical unmet medical needs in Greater China and other Asia Pacific markets. Its diverse portfolio includes eight clinical-stage drug candidates aimed at treating various conditions such as oncology, immunology, cardio-renal diseases, and infectious diseases. Everest Medicines aims to partner with innovative global companies to bring transformative pharmaceutical solutions to the Emerging Market, leveraging its expertise in clinical development, regulatory affairs, and business operations. The company's pipeline features several notable candidates, including Nefecon, EVER001, PTX-COVID19-B, and Eravacycline, among others.

Jianke is anonline B2C pharmacy and healthcare services platform.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

Swixx Biopharma is a specialized company that provides comprehensive representation for biopharma, over-the-counter (OTC), and medical device firms in Central and Eastern Europe (CEE). Founded in 2014 and based in Baar, Switzerland, Swixx Biopharma operates fully-owned affiliates across various CEE countries, including Albania, Bulgaria, Poland, and Romania, among others. The company aims to fill the gap left by multinational corporations that choose not to enter or exit specific markets or therapeutic areas. With a focus on rare diseases, oncology-hematology, specialty treatments, and self-medication, Swixx Biopharma leverages its research expertise to deliver effective health solutions tailored to the needs of the region.

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of treatments for immune-mediated dermatological diseases. Founded in 2016, Arcutis is focused on addressing unmet medical needs in dermatology by leveraging advances in immunology and inflammation. Its lead product candidate, a topical cream formulation of roflumilast, is undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. Additionally, the company is developing other innovative therapies, including a topical foam formulation for seborrheic dermatitis and scalp psoriasis, a selective small molecule inhibitor for hand eczema, and a specialized formulation designed for alopecia areata. Arcutis aims to provide differentiated therapies that effectively tackle persistent treatment challenges in serious skin conditions.

Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, designed for conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. In addition to inebilizumab, Viela Bio is developing VIB4920, aimed at preventing kidney transplant rejection and treating Sjögren's syndrome, and VIB7734, which targets cutaneous lupus erythematosus. The company has formed a strategic partnership with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, Viela Bio is committed to addressing critical pathways underlying autoimmune diseases to improve patient outcomes.

Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Sai Life Sciences Ltd. specializes in the discovery, contract development, and manufacturing of pharmaceuticals for clients in the biotechnology and pharmaceutical sectors. The company offers a comprehensive range of services, including discovery solutions such as synthetic and medicinal chemistry, toxicology, and pharmacology, as well as development services like analytical method validation, stability studies, and formulation development. Additionally, Sai Life Sciences provides manufacturing capabilities for late-phase and commercial products, along with technology transfer services. With a presence in key markets including India, the United States, the European Union, and Japan, the company has established research and manufacturing facilities in Hyderabad, Pune, Bidar, Cambridge, and Manchester. Founded in 1999 and formerly known as SAI Advantium Pharma Limited, Sai Life Sciences is focused on helping its clients accelerate the development of innovative medicines while minimizing risks and costs.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative small molecule targeted therapies for oncology. The company designs a range of tyrosine kinase inhibitors (TKIs) aimed at addressing genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. Its lead drug candidate, repotrectinib, is currently under evaluation in the ongoing Phase I/II TRIDENT-1 trial, targeting patients with ROS1+ advanced non-small-cell lung cancer and those with ROS1+, NTRK+, or ALK+ advanced solid tumors. Additionally, Turning Point's pipeline includes other multi-targeted drug candidates, such as TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, which is an ALK inhibitor in preclinical development. Founded in 2013 and headquartered in San Diego, California, the company aims to advance precision medicine in oncology by addressing unmet medical needs.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapeutics aimed at enhancing the effectiveness of radiotherapy for cancer patients. The company's lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer. Additionally, GC4419 is being evaluated in Phase IIa trials for the treatment of radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing another candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. The company's research is focused on targeting oxygen metabolic pathways to improve patient outcomes in radiation therapy, and GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration.

Jianke is anonline B2C pharmacy and healthcare services platform.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing innovative therapies for gastrointestinal and immunological diseases. Headquartered in Dublin, Ireland, with an additional office in Solana Beach, California, the company aims to address unmet clinical needs through its proprietary oral drug delivery technology. This technology enhances the bioavailability of difficult-to-formulate drugs, allowing for effective systemic or localized delivery within the gastrointestinal tract. Sublimity Therapeutics' product portfolio includes treatments for conditions such as ulcerative colitis, Crohn’s disease, graft versus host disease, and transplant rejection, as well as SmPill formulations for various gastrointestinal disorders. The company's lead product is STI-0529, specifically designed for moderate to severe ulcerative colitis. Founded in 2000 and formerly known as Sigmoid Pharma, Sublimity Therapeutics is committed to advancing oral pharmaceutical formulation technologies to improve patient outcomes in its targeted therapeutic areas.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, dedicated to developing and commercializing innovative antibody-based therapies for cancer treatment. The company is advancing several product candidates, including naxitamab, currently in Phase 2 clinical trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, as well as GD2-GD3 Vaccine, also in Phase 2 for high-risk neuroblastoma. Additionally, omburtamab is under development for desmoplastic small round cell tumors and pediatric central nervous system cancers. Y-mAbs is also exploring huB7-H3 for B7-H3 positive adult solid tumors and huCD33 BsAb for hematological cancers. The company collaborates with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to enhance its antibody constructs through the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs aims to bring multiple cancer therapies to FDA approval, with a focus on reducing long-term toxicities associated with traditional chemotherapies. Its first FDA-approved product, DANYELZA, targets GD2, a marker in various neuroectoderm-derived tumors and sarcomas.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, dedicated to developing and commercializing innovative antibody-based therapies for cancer treatment. The company is advancing several product candidates, including naxitamab, currently in Phase 2 clinical trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, as well as GD2-GD3 Vaccine, also in Phase 2 for high-risk neuroblastoma. Additionally, omburtamab is under development for desmoplastic small round cell tumors and pediatric central nervous system cancers. Y-mAbs is also exploring huB7-H3 for B7-H3 positive adult solid tumors and huCD33 BsAb for hematological cancers. The company collaborates with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to enhance its antibody constructs through the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs aims to bring multiple cancer therapies to FDA approval, with a focus on reducing long-term toxicities associated with traditional chemotherapies. Its first FDA-approved product, DANYELZA, targets GD2, a marker in various neuroectoderm-derived tumors and sarcomas.

Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Homology Medicines, Inc., established in 2015 and headquartered in Bedford, Massachusetts, is a biotechnology company focused on developing genetic medicines for patients with rare genetic diseases. The company's proprietary platform employs human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies or nuclease-free gene editing treatments in vivo, targeting various disease-relevant tissues such as the liver, central nervous system, and eye. Homology Medicines has two lead product candidates: HMI-102, currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, and HMI-103, intended for PKU treatment in pediatric patients. Additionally, the company is developing HMI-202 to treat metachromatic leukodystrophy. Homology Medicines aims to cure the underlying causes of these diseases by leveraging its robust intellectual property portfolio and experienced management team with a proven track record in rare disease therapeutics.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Amicus SA is a pharmaceutical company based in Baar, Switzerland, established in 2013. It specializes in representing research-based pharmaceutical and healthcare companies in the Balkans and the Baltics, particularly in regions where the original companies do not maintain a direct presence. The company offers a range of services, including marketing and sales, regulatory affairs, reimbursement and market access, and logistics management. Amicus also collaborates with local partners for manufacturing and packaging, and provides risk management services encompassing pharmacovigilance, compliance, and quality assurance. Its team is composed of skilled managers and medical professionals committed to delivering modern medicines to these markets while upholding ethical standards in its operations.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Vitaeris Inc. is a biopharmaceutical company based in Vancouver, Canada, that specializes in developing treatments for chronic inflammatory diseases using the anti-interleukin-6 monoclonal antibody, clazakizumab. Founded in 2016, the company has secured global exclusive rights to clazakizumab from Alder Biopharmaceuticals and is focused on creating innovative therapeutic options aimed at improving recovery for organ transplant recipients and other patients suffering from chronic conditions. As of June 2020, Vitaeris operates as a subsidiary of CSL Limited, allowing it to leverage additional resources for its research and development efforts.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapeutic antibodies for inflammation and immuno-oncology. The company’s key product candidates include Etokimab, an anti-IL-33 treatment for atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis; and several immune cell modulating antibodies, including checkpoint agonists for autoimmune diseases. AnaptysBio's pipeline features notable immuno-oncology candidates such as TSR-042 (anti-PD-1), TSR-022 (anti-TIM-3), and TSR-075 (anti-PD-1/LAG-3 bispecific). The company employs a proprietary platform based on somatic hypermutation for antibody discovery and optimization, addressing unmet medical needs in therapeutic applications. AnaptysBio has formed partnerships with various organizations, including TESARO and Celgene, to enhance its research and development efforts. Founded in 2005, AnaptysBio has established itself in the biotechnology sector as a developer of innovative therapies targeting significant health challenges.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Advanced Accelerator Applications S.A., founded in 2002 and based in Saint Genis Pouilly, France, specializes in the development, production, and commercialization of molecular nuclear medicine products for diagnostic and therapeutic purposes. The company offers a range of products including oxodotreotides, dotatate injections, edotreotide solutions, flurochol, and gluscan, which are used in oncology, cardiology, and neurology. Additionally, it provides innovative solutions like LysaKare for reducing kidney radiation exposure during therapy, DOPAVIEW for rapid tissue accumulation, CARDIOGEN for producing rubidium chloride, NEUROLITE for radiopharmaceutical preparation, LUMARK as a radiopharmaceutical precursor, and LEUKOKIT for leukocyte separation and labeling. The company's theragnostic platform uses radiolabeling to target tumor cells, aiding in diagnosis, monitoring, and staging. Advanced Accelerator Applications operates as a subsidiary of Novartis AG.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.